Highlights GSK plc

Equities

GSK

GB00BN7SWP63

Real-time Estimate Cboe Europe Other stock markets 07:56:55 2024-04-29 am EDT			5-day change	1st Jan Change
1,663 ^GBX	+0.62%		+1.37%	+14.60%

01:29pm	GSK : UBS reaffirms its Buy rating	ZD
08:52am	Hipgnosis Songs Fund backs new Blackstone bid	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hipgnosis Songs Fund backs new Blackstone bid	02:52am	AN
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	Apr. 25	MT
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24	MT
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	Apr. 24
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	Apr. 24	MT
GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli	Apr. 24	CI
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	Apr. 24	MT
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	Apr. 17	CI
GSK: shingles virus effective for over 10 years	Apr. 17	CF
GSK hails data on Shingles vaccine and gonorrhoea treatment	Apr. 17	AN
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	Apr. 17	MT
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	Apr. 17	MT
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin	Apr. 17	CI
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2%	Apr. 16	MT
GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY Vaccine Candidate	Apr. 16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST